Press

Braxia Scientific Announces Board Appointment

Sep 22 • 2 min read

Braxia Scientific Corp, (CSE: BRAX | OTC: BRAXF | FWB: 4960) a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce that Leann Taylor, President and COO of KetaMD, Inc., has joined the board of directors. KetaMD, a telemedicine platform recently acquired by…

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program

Sep 21 • 2 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW | OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has recently received a cash payment of approximately CDN $450K from a refundable tax credit program from its clinical research work in Australia. “Algernon tries to conduct as much of its clinical research in Australia as possible…

Biomind Labs Announces Completion of Dosing in Phase II Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

Sep 21 • 2 min read

Biomind Labs Inc. (NEO: BMND | OTC: BMNDF | FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce the completion of dose administration of 30 healthy subjects in…

Cybin Achieves Research and Development Milestones Ahead of Projected Timelines

Sep 21 • 3 min read

Cybin Inc. (NEO:CYBN | NYSE AMERICAN:CYBN), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, announced that it has successfully achieved its research and development milestones that helped to build and progress its innovative pipeline of investigational psychedelic therapeutics ahead of projected timelines. These milestones were set forth in the acquisition agreement of Adelia Therapeutics Inc….

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit

Sep 21 • 2 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at Jefferies Innovation in Mental Health Summit at 8:30am ET on 22 September 2022. A live audio webcast of the fireside chat will be accessible…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435